Yolk sac tumor is the most common malignant neoplasm of germ cell origin and usually occurs in infant testes or ovaries. On rare occasions, the tumor arises from extragonadal sites, including the sacrococcygeal region, uterus, vagina, prostate, retroperitoneum, liver, mediastinum (commonly in the anterior), pineal gland, and third ventricle. Yolk sac tumors have an unfavorable prognosis, if not treated aggressively. We report the case of a 3-year-old boy with a primary posterior mediastinal yolk sac tumor who was managed initially with surgery, followed by chemotherapy and had a favorable prognosis. In the literature on yolk sac tumors presenting as a mediastinal mass, pediatric germ cell tumors have been reported very rarely in the posterior mediastinum.
Introduction
Extragonadal yolk sac tumor (YST) is a very rare neoplasm that represents 3-5% of all pediatric malignancies, most frequently observed in infants and children under 4 years of age. It is a highly variable and aggressive tumor that requires immediate and definite diagnosis and treatment (1) .
Mediastinal masses represent the most common thoracic masses in childhood, the majority of which (almost 90%) are of neurogenic origin. The differential diagnosis includes germ cell tumors (GCTs), lymphomas, bronchogenic cysts, pathologic conditions of the thymus gland, pulmonary malformations, enteric duplications and hernias, and pathologies of the spinal cord and vertebrae. Primary mediastinal GCTs constitute 10-15% of mediastinal masses and represent the most common site of primary extragonadal GCTs. Pediatric GCTs appear with a bimodal age distribution, with a small peak during infancy and then a higher incidence after puberty. A wide range of signs and symptoms can be observed in children with mediastinal GCTs that reflect the primary pathologic condition and the functional compromise (mostly compression) of the surrounding structures (2) .
In this article, we describe a rare case of an extragonadal YST originating from the posterior mediastinum in a 3-year-old boy.
Case
A 3-year-old boy was referred to our department with a 5-day history of hyperpyrexia. At the physical examination, decreased respiratory sounds of the left lung were noted. The remaining physical and neurologic examinations were unremarkable. The child had an unremarkable perinatal and medical history, normal growth and development, and an unremarkable family history.
Full blood count, biochemical analysis, and arterial blood gases were found normal: PCO 2 Chest X-ray revealed extended right-sided pleural effusion. A computed tomography (CT) scan of the chest revealed extended right-sided pleural effusion, compression atelectasis of the right lower lobe, and a large paraspinal (T8-T12) lobulated mass (6.5x5.5 cm) (Fig. 1) . For further evaluation, a magnetic resonance image (MRI) of the chest was obtained. The MRI showed a large right paraspinal soft tissue mass located in the posterior mediastinum extending from the T8 to T12 vertebrae, which did not cross the midline. The mass was lobulated, and heterogeneously enhancing with multiple internal necrotic-cystic lesions. MRI also revealed extended rightsided pleural effusion, and compression atelectasis of the right lower lobe (Fig. 2) . No metastatic lesions were found in a bone scan.
A standard right thoracentesis was performed and antibiotic treatment with cefuroxime was started, which resulted in complete resolution of the pleural effusion. One week later, the patient was stable and afebrile. Thoracotomy and biopsy of the mediastinal mass was performed. Histologic studies showed a germ cell tumor with biochemical and morphologic characteristics consistent with YST. The patient received combination chemotherapy including bleomycin-etoposide-cisplatin (BEP). In total, the boy received 4 chemotherapy cycles. Three months later, by the end of the protocol, aFP levels were found within normal limits (5.3 ng/mL) and a subsequent MRI scan revealed complete resolution of the tumor and pleural effusion. To date, the patient remains free of disease and complications 4 years after treatment. Written informed consent was given by the patient's parents. The three sensitive diagnostic markers for YST in immunocytochemistry are aFP, glypican-3, and SALL4. Serum aFP levels are elevated in patients with YSTs and usually decrease within 2 to 3 weeks after treatment. Assessment of serum AFP levels is useful for diagnosing YSTs and also in monitoring response to therapy and prognosis (5) . The mean and standard deviation of normal serum aFP levels in infants at various ages are shown in Table 1 .
The overall prognosis for mediastinal GCTs is unfavorable, partly because the tumors are far advanced at the time of diagnosis, but also because some tumors contain embryonal cell carcinoma, choriocarcinoma, and yolk sac elements, which are very aggressive (6) . The prognosis of YST depends partly on its location. Although pure testicular YST in infants has at least a 75% 5-year survival rate, mediastinal YST is much more aggressive (7). There is a remarkable improvement in the survival of patients with YST because of the advent of chemotherapy. The single most important prognostic indicator is whether the tumor mass can be completely excised before or after chemotherapy. Primary mediastinal YSTs have worse survival compared with other extragonadal YSTs due to the large tumor bulk at diagnosis, resistance to chemotherapy, and difficulty in removing all residual disease after chemotherapy. Early detection and therapy is important because the tumor shows good response to surgery and chemotherapy (8) .
In the past, YSTs were nearly uniformly fatal, regardless of the primary location. However, the survival rate of patients with YST has been significantly improved because of the application of cisplatin-based multi-agent chemotherapy. Currently, initial surgery followed by adjuvant chemotherapy including bleomycin, etoposide, and cisplatin (BEP) is considered the standard for the treatment of YST (9) . Compared with other regimens, BEP appears to be the best active first-line option for primary, metastatic, or recurrent disease. It should also be stressed that secondary cytoreductive surgery could play an important role when tumors are limited and resistant to chemotherapy. Regarding the follow-up of chemotherapy, the determination of initially elevated markers (AFP) should be repeated before each cycle of therapy, soon after the end of the treatment and during the 2 years after the end of chemotherapy. As mentioned above, the commonest site for extragonadal lesions is the sacrococcygeal region. The anterior mediastinum is the second most common extragonadal location for YSTs; the posterior mediastinum is a very rare extragonadal location (7, 10) . Knapp et al. reported approximately 80 such cases, the vast majority occurring in young adult males (6) . To our knowledge, there are no previous reports documenting the posterior mediastinum as a primary site for an extragonadal YST.
